Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minLeaning Bearish
5 minStrong Bullish
Daily trend turns up above $41.77
Key levels
Resistance$17.52
Resistance$16.75
Latest news & SEC filings
NewsEnanta Pharmaceuticals begins search for new CEO
LegalEnanta Pharmaceuticals loses '265 patent in Pfizer dispute at European court
LegalEnanta Pharmaceuticals sues Pfizer over Paxlovid patent in Europe
All ENTA news →Enanta Pharmaceuticals is a biotechnology company that creates oral medicines based on chemistry and drug discovery. It develops treatments for viral infections, including respiratory syncytial virus, COVID-19 and hepatitis B, and for immune conditions such as chronic hives and eczema. The company discovered glecaprevir, a hepatitis C drug licensed to AbbVie and sold within the MAVYRET/MAVIRET combination. It operates in the United States.
Based on the company's 10-K filed Nov 19, 2025.
Nasdaq · Healthcare
SEPT Low Target
$20.00
SEPT Mid Target
$20.00
SEPT High Target
$20.00
Analyst Consensus
$20.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ENTA.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$17.23
15
Moat Score
NONE
3/9
Piotroski Score
-2.1
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-3.4%
3yr Revenue CAGR
-8.8%
EPS Growth YoY
29.93%
FCF Growth YoY
66.7%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for ENTA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:59:19 | $11.61 | 1,297 | $$15K | BUY |
| 20:57:30 | $11.64 | 1,000 | $$12K | MIDPOINT |
| 20:36:09 | $11.64 | 1,111 | $$13K | BUY |
| 18:12:48 | $11.56 | 1,030 | $$12K | BUY |
| 18:05:39 | $11.54 | 2,004 | $$23K | SELL |
5 dark pool trades shown · $$75K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for ENANTA PHARMACEUTICALS INC (ENTA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ENANTA PHARMACEUTICALS INC (ENTA) is at $11.60, up 3.39% (+$0.38) at the Nov 11, 2026 close.
Latest ENTA news — Nov 11, 2026: Enanta Pharmaceuticals begins search for new CEO · Oct 30, 2026: Enanta Pharmaceuticals loses '265 patent in Pfizer dispute at European court
The average analyst price target for ENTA is $20.00, ranging from $20 to $20, based on 1 analysts.
Analyst ratings for ENTA: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
ENTA last reported on Aug 10, 2026: EPS -$0.67 vs -$0.51 expected — a miss of 31.5%.
ENTA does not currently pay a dividend.
Resistance: $16.75, $17.52, $18.31.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 11, 2026: Enanta Pharmaceuticals begins search for new CEO · Oct 30, 2026: Enanta Pharmaceuticals loses '265 patent in Pfizer dispute at European court · Oct 29, 2026: Enanta Pharmaceuticals sues Pfizer over Paxlovid patent in Europe